Literature DB >> 8690284

Neoadjuvant chemotherapy in uterine papillary serous carcinoma.

E Resnik1, J B Taxy.   

Abstract

Uterine papillary serous carcinoma (UPSC) is an aggressive variant of endometrial cancer that frequently imitates serous carcinoma of the ovary in its clinical presentation and histologic appearance. Unlike the ovarian lesion, however, it is known to be particularly resistant to chemotherapy. A patient with a putative diagnosis of unresectable Stage IV ovarian cancer was treated with three cycles of neoadjuvant chemotherapy containing paclitaxel and carboplatin. After a remarkable response, interval cytoreductive surgery was performed. A primary endometrial tumor with the pathologic features of UPSC was found. To our knowledge, the use of paclitaxel-containing chemotherapy in UPSC has not been reported. We suggest that this therapy might be useful in the treatment of patients with advanced uterine papillary serous carcinoma, as well as in an adjuvant setting.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8690284     DOI: 10.1006/gyno.1996.0201

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  8 in total

1.  Neoadjuvant chemotherapy versus primary cytoreductive surgery for stage IV uterine serous carcinoma.

Authors:  Ivy Wilkinson-Ryan; Antonina I Frolova; Jingxia Liu; L Stewart Massad; Premal H Thaker; Matthew A Powell; David G Mutch; Andrea R Hagemann
Journal:  Int J Gynecol Cancer       Date:  2015-01       Impact factor: 3.437

2.  Class III β-tubulin overexpression within the tumor microenvironment is a prognostic biomarker for poor overall survival in ovarian cancer patients treated with neoadjuvant carboplatin/paclitaxel.

Authors:  Dana M Roque; Natalia Buza; Michelle Glasgow; Stefania Bellone; Ileana Bortolomai; Sara Gasparrini; Emiliano Cocco; Elena Ratner; Dan-Arin Silasi; Masoud Azodi; Thomas J Rutherford; Peter E Schwartz; Alessandro D Santin
Journal:  Clin Exp Metastasis       Date:  2013-09-05       Impact factor: 5.150

3.  Neoadjuvant chemotherapy followed by surgery for advanced-stage endometrial cancer.

Authors:  N M de Lange; N P M Ezendam; J S Kwon; I Vandenput; D Mirchandani; F Amant; L J M van der Putten; J M A Pijnenborg
Journal:  Curr Oncol       Date:  2019-04-01       Impact factor: 3.677

Review 4.  Systemic therapy for advanced or recurrent endometrial carcinoma.

Authors:  G F Fleming
Journal:  Curr Oncol Rep       Date:  1999-09       Impact factor: 5.075

5.  Coordinate patterns of estrogen receptor, progesterone receptor, and Wilms tumor 1 expression in the histopathologic distinction of ovarian from endometrial serous adenocarcinomas.

Authors:  Oluwole Fadare; Samuel James; Mohamed M Desouki; Dineo Khabele
Journal:  Ann Diagn Pathol       Date:  2013-05-21       Impact factor: 2.090

6.  Neoadjuvant chemotherapy followed by interval debulking surgery in patients with serous endometrial cancer with transperitoneal spread (stage IV): a new preferred treatment?

Authors:  I Vandenput; B Van Calster; A Capoen; K Leunen; P Berteloot; P Neven; Ph Moerman; I Vergote; F Amant
Journal:  Br J Cancer       Date:  2009-06-30       Impact factor: 7.640

7.  Clinicopathologic study in uterine cancer.

Authors:  I Vandenput
Journal:  Facts Views Vis Obgyn       Date:  2011

8.  The use of neoadjuvant chemotherapy in advanced endometrial cancer.

Authors:  L Philp; A Kanbergs; J St Laurent; W B Growdon; C Feltmate; A Goodman
Journal:  Gynecol Oncol Rep       Date:  2021-02-08
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.